S1 Biopharma is an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions.
Our purpose is to create safe and effective new medicines for the treatment of HSDD in women, and HSDD in men.
HSDD is an under-recognized condition for which there is no pharmacological treatment currently approved by the U.S. Food and Drug Administration.
Our lead product, Lorexys, is an orally administered tablet for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and symptoms of generalized Female Sexual Dysfunction (FSD). Additional products in development include S1P-205, an oral tablet for HSDD in men.
Our lead product, Lorexys, is an orally administered tablet for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and symptoms of generalized Female Sexual Dysfunction (FSD). Additional products in development include S1P-205, an oral tablet for HSDD in men.